Navigation Links
PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
Date:10/21/2009

PRINCETON, N.J., Oct. 21 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, today announced its participation at the 8th Annual Partnerships in Clinical Trials Conference taking place at the World Trade Center in Rotterdam, The Netherlands from November 3-6, 2009.

At the conference, top management will discuss some of the most important issues to impact the industry growth and financial performance of CROs and their clients: the changing marketplace for drug development services, the industry's move to the fast growing emerging markets, and the clinical implications of developing biosimilar therapeutics.

Wednesday, 4 November 2009

Jeffrey P. McMullen, President and CEO of PharmaNet Development Group, will give a keynote presentation, "CRO Growth Opportunities in a More Challenging Market Environment."

Dr. Robert Reekie, Senior Executive Vice President Operations, Europe, Asia-Pacific, will chair a session entitled "Emerging Economies - Your Strategic Expansion for Cost Reduction and Patient Recruitment."

Thursday, 5 November 2009

Dr. Pablo Fernandez, Senior Vice President, Medical Affairs, will present "A Practical Overview of Outsourced Clinical Development for Biosimilars."

Conference attendees are invited to visit booth number 94 where PharmaNet Development Group's international team of experts will discuss how the Company helps clients reach their goal of delivering safe and effective therapeutics to patients.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com .

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    Email: ahess@pharmanet.com

SOURCE PharmaNet Development Group, Inc.


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Promising Cystic Fibrosis Compound on Track for Development
5. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
6. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
7. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
8. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
9. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
10. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
11. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... The pen needles market is projected to ... billion in 2016, growing at a CAGR of 11.2% ... Over the years, the pen needles market has witnessed ... growing demand for safety injections in the healthcare industry. ... pen needles with an aim to reduce pain, increase ...
(Date:12/6/2016)... -- Nearly 30 million people in the United ... 1 However, nearly 40% of diabetes patients in ... significant glucose variability. 2 These patients are at high ... left untreated, hyperglycemia can lead to cardiovascular disease, nerve ... As part of Diabetes Awareness Month, ...
(Date:12/6/2016)... opioids commonly used for pain management for workplace injuries, employers now ... to nationwide fatalities. The synthetic opioid called U-47700, or ... morphine, resulting in likelihood of addiction, abuse or death. ... , , ... for HMC HealthWorks, explained the opioid drug is less expensive yet ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors ... said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 ... drop zones. Editors can select from a variety of flip book animations. In Addition, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Bioelectronic ... Plus for consumers and healthcare professionals to manage chronic and acute pain. ... treatment modalities available in a single device. The announcement is part of ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “The Road ... is an everyday trial, not a one hour a week showing of hands. “The ... businessman. , Tom begins, “Perhaps you are familiar with the brass ring that you ...
(Date:12/7/2016)... ... ... With God: Inspirational Lessons from My Life's Journey”: a sometimes serious, sometimes humorous ... in their lives. “Walking With God: Inspirational Lessons from My Life's Journey” is the ... , Sanford says, “I enjoy sharing the true stories in my book as examples ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... for individuals impacted by cerebral cavernous angiomas, was awarded a grant from the ... patient engagement program. New Mexico has more people with cavernous angioma than anywhere ...
Breaking Medicine News(10 mins):